Fabisiak A, Caban M, Dudek P, Strigac A, Malecka-Wojciesko E, Talar-Wojnarowska R
Therap Adv Gastroenterol. 2025; 18:17562848241309871.
PMID: 39758970
PMC: 11694300.
DOI: 10.1177/17562848241309871.
Wang J, Kang G, Lu H, de Marco A, Yuan H, Feng Z
Clin Transl Med. 2024; 14(3):e1636.
PMID: 38533646
PMC: 10966562.
DOI: 10.1002/ctm2.1636.
Solitano V, Ma C, Hanzel J, Panaccione R, Feagan B, Jairath V
Gastroenterol Hepatol (N Y). 2023; 19(5):251-263.
PMID: 37799456
PMC: 10548249.
Abdullah I, AlMojil K, Shehab M
Diseases. 2022; 10(4).
PMID: 36412596
PMC: 9680431.
DOI: 10.3390/diseases10040102.
Goessens L, Colombel J, Outtier A, Ferrante M, Sabino J, Judge C
United European Gastroenterol J. 2021; 9(10):1136-1147.
PMID: 34694746
PMC: 8672088.
DOI: 10.1002/ueg2.12170.
Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.
Yu N, Sarwal D, Ash R, Aslinia F
BMJ Case Rep. 2021; 14(10).
PMID: 34645625
PMC: 8515434.
DOI: 10.1136/bcr-2021-243500.
Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention.
Pagnini C, Cominelli F
Int J Mol Sci. 2021; 22(19).
PMID: 34638616
PMC: 8508644.
DOI: 10.3390/ijms221910273.
Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
Gold S, Steinlauf A
Gastroenterol Hepatol (N Y). 2021; 17(9):406-414.
PMID: 34602905
PMC: 8475252.
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.
Roberts K, Cubitt M, Carlton T, Rodrigues-Duarte L, Maggiore L, Chai R
Sci Rep. 2021; 11(1):19422.
PMID: 34593832
PMC: 8484351.
DOI: 10.1038/s41598-021-97236-0.
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.
Privitera G, Pugliese D, Lopetuso L, Scaldaferri F, Neri M, Guidi L
Therap Adv Gastroenterol. 2021; 14:17562848211006669.
PMID: 33995579
PMC: 8082976.
DOI: 10.1177/17562848211006669.
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
Olbjorn C, Rove J, Jahnsen J
Paediatr Drugs. 2020; 22(4):409-416.
PMID: 32378002
PMC: 7383034.
DOI: 10.1007/s40272-020-00396-1.
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
Liefferinckx C, Verstockt B, Gils A, Tops S, van Moerkercke W, Vermeire S
United European Gastroenterol J. 2019; 7(6):750-758.
PMID: 31316779
PMC: 6620879.
DOI: 10.1177/2050640619841538.
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor.
Pagnini C, Pizarro T, Cominelli F
Front Pharmacol. 2019; 10:671.
PMID: 31316377
PMC: 6611384.
DOI: 10.3389/fphar.2019.00671.
Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics.
Mao E, Lewin S, Terdiman J, Beck K
BMJ Open Gastroenterol. 2018; 5(1):e000243.
PMID: 30538822
PMC: 6254738.
DOI: 10.1136/bmjgast-2018-000243.
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.
Shim H, Chan P, Chuah S, Schwender B, Kong S, Ling K
JGH Open. 2018; 2(5):223-234.
PMID: 30483594
PMC: 6207060.
DOI: 10.1002/jgh3.12065.
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.
Paramsothy S, Rosenstein A, Mehandru S, Colombel J
Mucosal Immunol. 2018; 11(6):1558-1570.
PMID: 29907872
PMC: 6279599.
DOI: 10.1038/s41385-018-0050-3.
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease.
Liu E, Loomes D
Case Rep Med. 2017; 2017:5264216.
PMID: 29250117
PMC: 5698793.
DOI: 10.1155/2017/5264216.
